17.
Revenue
The
following table provides information about disaggregated revenue by product and services:
Schedule
of Disaggregated Revenue by Product and Services
| | |
2025 | | |
2024 | |
| | |
Year Ended December 31, | |
| | |
2025 | | |
2024 | |
| Product sales, net | |
$ | 13,175 | | |
$ | 35,336 | |
| Services | |
| 5,432 | | |
| 5,140 | |
| License, royalty and other | |
| 7,943 | | |
| 13,744 | |
| Total revenues | |
$ | 26,550 | | |
$ | 54,220 | |
The
following table provides changes in deferred revenue from contract liabilities:
Schedule of Changes in Deferred Revenue from Contract Liabilities
| | |
2025 | | |
2024 | |
| Balance at January 1 | |
$ | 6,255 | | |
$ | 6,020 | |
| Beginning Balance | |
$ | 6,255 | | |
$ | 6,020 | |
| Deferral of revenue (1)(3) | |
| 8,193 | | |
| 5,731 | |
| Recognition of unearned revenue (2) | |
| (6,394 | ) | |
| (5,496 | ) |
| Balance at December 31 | |
$ | 8,054 | | |
$ | 6,255 | |
| Ending Balance | |
$ | 8,054 | | |
$ | 6,255 | |
| |
(1) |
Deferral
of revenue includes $2,492 in 2025 resulting from payments received in advance of performance under the biobanking services storage
contracts that are recognized as revenue under the contract as performance is completed. |
| |
|
|
| |
(2) |
Recognition of unearned revenue for the year ended December 31, 2025 includes $3,492 that was included in the beginning
deferred revenue balance at January 1, 2025. |
| |
|
|
| |
(3) |
Deferral of revenue includes $2,890 in 2025 resulting from product purchase credits issued to Defeye as consideration
for Defeye’s Series Seed – 2 Preferred Stock (Note 22). |
|